Adam Colborn, JD, director of government relations for the Academy of Managed Care Pharmacy, discussed how providers can comfortably switch patients to biosimilars while minimizing anxieties, as well as the impacts prior authorization requirements can have on patient access.
Adam Colborn, JD, director of government relations for the Academy of Managed Care Pharmacy, analyzed approaches health care professionals can take to reduce patient anxieties when switching from a reference biologic to a biosimilar, and touched on the impact of prior authorization requirements on patient access to medications. Colborn presented at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting during a session titled, "Breaking Boundaries With Interchangeable Biosimilars: The Sequel," where he explained the regulatory landscape of interchangeable biosimilars, the outcome they have on formulary management and benefit design, as well as emerging regulatory trends.
As the director of government relations at AMCP, Colborn applies his experience in public policy and advocacy at the federal and state level to support the organization's mission and members.
Transcript
What are some strategies or approaches that health care professionals can employ to alleviate patient anxieties when transitioning from a reference biologic to a biosimilar?
I think it would be most useful for providers to receive additional education around biosimilar switching. I think it's not well understood right now, and there's additional education that can be done to empower providers to better inform their patients.
Right now, I think many providers feel that they don't have the information that they need in order to talk confidently about this with their patients. So, that's part of it, is the provider education. Additionally, thinking about biosimilars as comparable to generics is helpful—I think it's the clearest analogue. Everyone is very comfortable with generics now, but biosimilars are a little bit more recent, so that hasn't quite entered the consciousness the same way that the safety of switching from a brand name small molecule drug to a generic small molecule drug has.
What are your thoughts on the role of prior authorization requirements in the biosimilar space, and how do you believe they impact patient access to these medications?
I think that prior authorization, like other utilization management techniques, there's really no specific way that we can say this will impact utilization except for how it directs patients to whatever is potentially on a lower tier. So prior authorization, I think, is probably less significant than formulary tiers, step edits.
So a step therapy protocol would be more likely to direct a patient toward a lower-cost therapy through a biosimilar before potentially moving to a more expensive innovator product. As far as prior authorization goes, I think, that would primarily be implemented for a safety concern rather than a cost concern.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More